Comparing Smoking Treatment Programs for Lighter Smokers - 1
Information source: National Institute on Drug Abuse (NIDA)
Information obtained from ClinicalTrials.gov on December 31, 2007
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Tobacco Use Disorder
Intervention: nicotine transdermal system (Drug); bupropion (Drug); Medication Management (Behavioral); Mayo Counseling (Behavioral); placebo patch (Drug); placebo bupropion (Drug)
Phase: Phase 2
Status: Active, not recruiting
Sponsored by: National Institute on Drug Abuse (NIDA) Official(s) and/or principal investigator(s):
Peter W Gariti, Ph.D., Principal Investigator, Affiliation: University of Pennsylvania
Summary
The purpose of this study is to compare two different types of Food and Drug Administration
(FDA) approved smoking cessation medications (nicotine patch or bupropion) used in
conjunction with two levels of counseling.
Clinical Details
Official title: Comparing Smoking Treatment Programs for Lighter Smokers
Study design: Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Efficacy Study
Primary outcome: Completion of treatment and smoking cessation by two different types of medications and counseling types at 12, 26, and 52 weeks post-treatment initiation.
Secondary outcome: Delinate mediators associated with different treatment conditions (i.e., medication compliance, participant views of self-help written materials and counseling type.
Eligibility
Minimum age: 18 Years.
Maximum age: 75 Years.
Gender(s): Both.
Criteria:
Light smokers (6-15 cigarettes per day
Inclusion Criteria:
Mentally and physically stable, non-pregnant, light smokers (6-15 cigarettes per
day
Exclusion Criteria:
Please contact site for more information
Locations and Contacts
University of Pennsylvania, Philadelphia, Pennsylvania 19104 6178, United States
Additional Information
Starting date: September 2003
Ending date: April 2008
Last updated: December 19, 2007
|
